Management of autoimmune retinopathies with immunosuppression

Archives of Ophthalmology

Volumn 127, Issue 4, 2009, Pages 390-397

  Ferreyra, Henry A ^a,b   Jayasundera, Thiran ^a   Khan, Naheed W ^a   He, Shirley ^a   Lu, Ying ^a   Heckenlively, John R ^a,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMMUNOGLOBULIN; INFLIXIMAB; METHYLPREDNISOLONE ACETATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TRIAMCINOLONE ACETATE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAOCULAR PRESSURE; MALE; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; RETINOPATHY; SCHOOL CHILD; SEX DIFFERENCE; SIDE EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VISUAL FIELD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; AZATHIOPRINE; BLOTTING, WESTERN; CHILD; CYCLOSPORINE; DRUG THERAPY, COMBINATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MACULAR EDEMA; MALE; MIDDLE AGED; PARANEOPLASTIC SYNDROMES; PREDNISONE; RETINAL DISEASES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 65249182245     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2009.24     Document Type: Article

References (45)

1. Whitcup SM, Vistica BP, Milam AH, Nussenblatt RB, Gery I. Recoverin- associated retinopathy: a clinically and immunologically distinctive disease. Am J Ophthalmol. 1998;126(2):230-237.
2. Mizener JB, Kimura AE, Adamus G, Thirkill CE, Goeken JA, Kardon RH. Autoimmune retinopathy in the absence of cancer. Am J Ophthalmol. 1997;123(5):607-618.
3. Adamus G. Antirecoverin antibodies and autoimmune retinopathy. Arch Ophthalmol. 2000;118(11):1577-1578.
4. Heckenlively JR, Fawzi AA, Oversier J, Jordan BL, Aptsiauri N. Autoimmune retinopathy: patients with antirecoverin immunoreactivity and panretinal degeneration. Arch Ophthalmol. 2000;118(11):1525-1533.
5. Hajali M, Fishman GA. The prevalence of cystoid macular oedema on optical coherence tomography in retinitis pigmentosa patients without cystic changes on fundus examination [published online April 18, 2008]. Eye. doi:10.1038/eye.2008.110.
6. Heckenlively JR, Solish AM, Chant SM, Meyers-Elliott RH. Autoimmunity in hereditary retinal degenerations, II: clinical studies: antiretinal antibodies and fluorescein angiogram findings. Br J Ophthalmol. 1985;69(10):758-764.
7. Heckenlively JR, Jordan BL, Aptsiauri N. Association of antiretinal antibodies and cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol 1999;127(5):565-573.
8. Chan JW. Paraneoplastic retinopathies and optic neuropathies. Surv Ophthalmol. 2003;48(1):12-38.
9. Hooks JJ,Tso MO, Detrick B. Retinopathies associated with antiretinal antibodies. Clin Diagn Lab Immunol. 2001;8(5):853-858.
10. Weleber RG, Francis PJ. Differential diagnosis of the electronegative electroretinogram. In: Heckenlively JR, Arden JB, eds. Principles and Practice of Clinical Electrophysi- ology of Vision. 2nd ed. Cambridge, MA: MIT Press; 2006.
11. Adamus G, Machnicki M, Seigel GM. Apoptotic retinal cell death induced by antirecoverin autoantibodies of cancer-associated retinopathy. Invest Ophthalmol Vis Sci. 1997;38(2):283-291.
12. Adamus G, Machnicki M, Elerding H, Sugden B, BlockerYS, FoxDA. Antibodies to recoverin induce apoptosis of photoreceptor and bipolar cells in vivo. J Autoimmun. 1998;11(5):523-533.
13. Adamus G,Amundson D, Seigel GM, Machnicki M. Anti-enolase-α utoantibodies in cancer-associated retinopathy: epitope mapping and cytotoxicity on retinal cells. J Autoimmun. 1998;11(6):671-677.
14. Chant SM, Heckenlively J, Meyers-Elliott RH. Autoimmunity in hereditary retinal degeneration, I: basic studies. Br J Ophthalmol. 1985;69(1):19-24.
15. Heckenlively JR, Aptsiauri N, NusinowitzS, Peng C, Hargrave PA. Investigations of antiretinal antibodies in pigmentary retinopathy and other retinal degenerations. Trans Am Ophthalmol Soc. 1996;94:179-200.
16. Fishman GA, Gilbert LD, Fiscella RG, KimuraAE, Jampol LM. Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa. Arch Ophthalmol. 1989;107(10):1445-1452.
17. Grover S, Fishman GA, Fiscella RG, Adelman AE. Efficacy of dorzolamide hydrochloride in the management of chronic cystoid macular edema in patients with retinitis pigmentosa. Retina. 1997;17(3):222-231.
18. Fishman GA, Apushkin MA. Continued use of dorzolamide for the treatment of cystoid macular oedema in patients with retinitis pigmentosa. Br J Ophthalmol. 2007;91(6):743-745.
19. Apushkin MA, Fishman GA, Grover S, Janowicz MJ. Rebound of cystoid macular edema with continued use of acetazolamide in patients with retinitis pigmentosa. Retina. 2007;27(8):1112-1118.
20. Adamus G, Ren G, Weleber RG. Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy. BMC Ophthalmol. 2004;4:5-14.
21. Matsui Y, Mehta MC, Katsumi O, Brodie SE, Hirose T. Electrophysiological findings in paraneoplastic retinopathy. Graefes Arch Clin Exp Ophthalmol. 1992;230(4):324-328.
22. Jacobson DM, Thirkill CE, Tipping SJ. A clinical triad to diagnose paraneoplastic retinopathy. Ann Neurol. 1990;28(2):162-167.
23. Kashiwabara K, Nakamura H, Kishi K, et al. Cancer-associated retinopathy during treatment for small-cell lung carcinoma. Intern Med. 1999;38(7):597-601.
24. Guy J, Aptsiauri N. Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases. Arch Ophthalmol. 1999;117(4):471-477.
25. Subhadra C, DudekAZ, Rath PP, Lee MS. Improvement in visual fields in a patient with melanoma-associated retinopathy treated with intravenous immunoglobulin. J Neuroophthalmol. 2008;28(1):23-26.
26. Thirkill CE, Tait RC, Tyler NK, Roth AM, Keltner JL. The cancer-associated retinopathy antigen is a recoverin-like protein. Invest Ophthalmol Vis Sci. 1992; 33(10):2768-2772.
27. Polans AS, Buczylko J, Crabb J, Palczewski K. A photoreceptor calcium binding protein is recognized by autoantibodies obtained from patients with cancer- associated retinopathy. J Cell Biol. 1991;112(5):981-989.
28. Polans AS, WitkowskaD, Haley TL, Amundson D, Baizer L,Adamus G. Recoverin. a photoreceptor-specific calcium-binding protein, is expressed by the tumor of a patient with cancer-associated retinopathy. Proc Natl Acad Sci USA. 1995;92 (20):9176-9180.
29. Goldstein SM, Syed NA, Milam AH, Maguire AM, Lawton TJ, Nichols CW. Cancer- associated retinopathy. Arch Ophthalmol. 1999;117(12):1641-1645.
30. Adamus G, Aptsiauri N, Guy J, Heckenlively J, Flannery J, Hargrave PA. The occurrence of serum autoantibodies againstenolase in cancer-associated retinopathy. Clin Immunol Immunopathol. 1996;78(2):120-129.
31. Ohguro H, Ogawa K, Maeda T, Maeda A, Maruyama I. Cancer-associated retinopathy induced by both anti-recoverin and anti-hsc70 antibodies in vivo. Invest Ophthalmol Vis Sci. 1999;40(13):3160-3167.
32. Ohguro H, Ogawa K, NakagawaT. Recoverin and Hsc 70 are found as autoanti- gens in patients with cancer-associated retinopathy. Invest Ophthalmol Vis Sci. 1999;40(1):82-89.
33. Kikuchi T, Arai J, Shibuki H, Kawashima H, Yoshimura N. Tubby-like protein 1 as an autoantigen in cancer-associated retinopathy. J Neuroimmunol. 2000;103 (1):26-33.
34. Eichen JG, Dalmau J, Demopoulos A, Wade D, Posner JB, Rosenfeld MR. The photoreceptor cell-specific nuclear receptor is an autoantigen of paraneoplastic retinopathy. J Neuroophthalmol. 2001;21(3):168-172.
35. Kornguth SE, Kalinke T, Grunwald GB, Schutta H, Dahl D. Anti-neurofilamentan- tibodies in the sera of patients with small cell carcinoma of the lung and with visual paraneoplastic syndrome. Cancer Res. 1986;46(5):2588-2595.
36. Milam AH, Saari JC, Jacobson SG, Lubinski WP, Feun LG, Alexander KR. Auto- antibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy. Invest Ophthalmol Vis Sci. 1993;34(1):91-100.
37. Keltner JL, Thirkill CE. The 22-kDa antigen in optic nerve and retinal diseases. J Neuroophthalmol. 1999;19(2):71-83.
38. Potter MJ, Adamus G, Szabo SM, Lee R, Mohaseb K, Behn D. Autoantibodies to transducin in a patient with melanoma-associated retinopathy. Am J Ophthalmol. 2002;134(1):128-130.
39. Peek R, Verbraak F, Coevoet HM, Kijlstra A. Müller cell-specific autoantibodies in a patient with progressive loss of vision. Invest Ophthalmol Vis Sci. 1998; 39(10):1976-1979.
40. Heckenlively JR, Ferreyra HA. Autoimmune retinopathy: a review and summary. Semin Immunopathol. 2008;30(2):127-134.
41. Sawyer RA, Selhorst JB, Zimmerman LE, Hoyt WF. Blindness caused by photoreceptor degeneration as a remote effect of cancer. Am J Ophthalmol. 1976; 81(5):606-613.
42. Keltner JL, Roth AM, Chang RS. Photoreceptor degeneration: possible autoimmune disorder. Arch Ophthalmol. 1983;101(4):564-569.
43. Thirkill CE, FitzGerald P, Sergott RC, Roth AM, Tyler NK, Keltner JL. Cancer- associated retinopathy (CAR syndrome) with antibodies reacting with retinal, optic- nerve, and cancer cells. N Engl J Med. 1989;321(23):1589-1594.
44. Murphy MA, Thirkill CE, Hart WM Jr. Paraneoplastic retinopathy: a novel autoantibody reaction associated with small-cell lung carcinoma. J Neuroophthalmol. 1997;17(2):77-83.
45. Espandar L, O'Brien S, Thirkill C, Lubecki LA, Esmaeli B. Successful treatment of cancer-associated retinopathy with alemtuzumab. J Neurooncol. 2007;83 (3):295-302.